Wu Sam, Adamson Adewole S
University of North Carolina at Chapel Hill, Department of Dermatology, Chapel Hill, North Carolina.
Dermatol Online J. 2019 Feb 15;25(2):13030/qt4j44w7w6.
Enfortumab vedotin is an antibody-drug conjugate targeting nectin-4 and is being studied in the treatment of various epithelial carcinomas including urothelial carcinoma; early data suggests efficacy and tolerability. Rash has been described as an adverse event associated with treatment with enfortumab vedotin, but has not been characterized to date. We report a patient with metastatic urothelial carcinoma treated with enfortumab vedotin who developed erythematous, scaly papules and plaques on his torso and extremities with corresponding histologic features of vacuolar interface dermatitis and maturation disarray of keratinocytes. He was successfully treated with topical corticosteroids. Cutaneous toxicity appears to be a common adverse reaction in this growing class of antibody-drug conjugates.
恩杂鲁胺是一种靶向Nectin-4的抗体药物偶联物，目前正在进行治疗包括尿路上皮癌在内的各种上皮癌的研究；早期数据显示了其疗效和耐受性。皮疹已被描述为与恩杂鲁胺治疗相关的不良事件，但迄今为止尚未对其进行特征描述。我们报告了一名接受恩杂鲁胺治疗的转移性尿路上皮癌患者，他的躯干和四肢出现了红斑、鳞屑性丘疹和斑块，组织学特征为空泡状界面皮炎和角质形成细胞成熟紊乱。他通过外用糖皮质激素成功治愈。皮肤毒性似乎是这类不断增加的抗体药物偶联物中的常见不良反应。
